Figure 4.
Effects of rosiglitazone on phorbol-12-myristate 13-acetate (PMA)-stimulated tumour necrosis factor-α (TNF-α) release from monocytes (A) and monocyte-derived macrophages (B) of selected non-smoker and smoker coronary heart disease patients. Cells were challenged with increasing concentrations of rosiglitazone (10−10 to 10−5 M) for 1 h and then stimulated by PMA (10−7 M) for 24 h. On the left: % inhibition by rosiglitazone; on the right: reversal by GW9662, at 10−6 M. Results are mean ± SEM; n= 4. °P < 0.01 versus smokers; *P < 0.05 versus PMA; ***P < 0.001 versus PMA. Note the different scale for TNF-α release in B.